TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$13.14
−1.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 29.1M | 13.1M | 10.1M | 7.8M | — |
| Cost of Revenue | 5.7M | 8.6M | 7.8M | 4.7M | — |
| Gross Profit | 23.4M | 4.5M | 2.3M | 3.0M | — |
| Operating Expenses | |||||
| R&D Expense | 63.9M | 44.5M | 40.4M | 86.7M | 81.9M |
| SG&A Expense | 99.2M | 85.8M | 40.1M | 34.8M | 30.2M |
| General & Admin Expense | 36.0M | — | 3.4M | 34.8M | 30.2M |
| Selling & Marketing Expense | — | — | 36.7M | — | — |
| Other Expenses | 25.7M | — | 58.5M | — | — |
| Total Operating Expenses | 188.8M | 130.2M | 139.0M | 121.4M | 112.1M |
| Cost and Expenses | 194.5M | 138.8M | 146.8M | 126.1M | 112.1M |
| Operating Income (EBIT) | (165.4M) | (125.7M) | (136.7M) | (118.4M) | (112.1M) |
| Non-Operating | |||||
| Interest Income | 3.9M | 4.1M | — | — | 1.9M |
| Interest Expense | — | 89.0K | — | — | — |
| Net Interest Income | 3.9M | 4.1M | — | — | 1.9M |
| Other Non-Op Income/Expense | 5.8M | 1.7M | 6.7M | 1.7M | 1.9M |
| Non-Operating Income (excl Interest) | (5.8M) | (1.8M) | (59.0M) | (1.7M) | (1.9M) |
| EBT (Pre-Tax Income) | (159.7M) | (124.0M) | (130.0M) | (116.7M) | (110.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (159.7M) | (124.0M) | (130.0M) | (116.7M) | (110.2M) |
| Earnings from Cont. Ops | (159.7M) | (124.0M) | (130.0M) | (116.7M) | (110.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (159.7M) | (124.0M) | (130.0M) | (116.7M) | (116.9M) |
| Per Share | |||||
| Basic EPS | ($13.24) | ($14.57) | ($176.60) | ($6,368.84) | ($811.68) |
| Diluted EPS | ($13.24) | ($14.57) | ($176.60) | ($6,368.84) | ($811.68) |
| Revenue Per Share | $1.75 | $1.54 | $4.46 | $4.24 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 16.6M | 8.5M | 2.3M | 1.8M | 3.1M |
| Diluted Shares Outstanding | 16.6M | 8.5M | 2.3M | 1.8M | 3.1M |
| Profitability Metrics | |||||
| EBITDA | (157.6M) | (122.0M) | (74.3M) | (112.4M) | (109.0M) |
| D&A | 2.1M | 1.9M | 3.4M | 4.3M | 1.3M |
| EBIT | (159.7M) | (123.9M) | (77.7M) | (116.7M) | (110.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026